A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2– Metastatic Breast Cancer

A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2– Metastatic Breast Cancer

PIK3CA mutation frequency varies among breast cancer (BC) subtypes. Recent evidence suggests combination therapy with the PI3K inhibitor (PI3Ki) alpelisib and endocrine therapy (ET) improves response rates and progression-free survival (PFS) in PIK3CA-mutant, hormone receptor positive (HR+) BC versu...

Full description

Bibliographic Details
Main Authors:	Elizabeth J. Anderson, Lea E. Mollon, Joni L. Dean, Terri L. Warholak, Ayal Aizer, Emma A. Platt, Derek H. Tang, Lisa E. Davis
Format:	Article
Language:	English
Published:	Hindawi Limited 2020-01-01
Series:	International Journal of Breast Cancer
Online Access:	http://dx.doi.org/10.1155/2020/3759179

Similar Items

PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers
by: Carlos A. Castaneda, et al.
Published: (2014-12-01)

Alpelisib: A Well-Tolerated Treatment Option for Patients with HR-Positive, HER2-Negative PIK3CA-Mutated Advanced Breast Cancer
by: Fei-Yu Diao
Published: (2021-10-01)

PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
by: Nicola Fusco, et al.
Published: (2021-03-01)

PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021
by: Editorial Board
Published: (2021-08-01)

Physician survey in the treatment of HR+/HER2 − metastatic breast cancer in Egypt
by: E. Aboelkheir, et al.
Published: (2021-04-01)

PIK3CA in colorectal cancer
by: Gieri eCathomas
Published: (2014-03-01)

Correlation between circulating cell‐free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA‐mutated metastatic breast cancer
by: Annette R. Kodahl, et al.
Published: (2018-06-01)

Liver uptake on bone scan for prostate cancer metastatic workup
by: Alain Mwamba Mukendi
Published: (2019-09-01)

Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2- Metastatic Breast Cancer
by: Yan Song, et al.
Published: (2015-09-01)

Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2-Metastatic Breast Cancer
by: Yan Song, et al.
Published: (2015-01-01)

Significance of EGFR/HER2 Expression and PIK3CA Mutations in Giant Cell Tumour of Bone Development
by: Raja Amri, et al.
Published: (2020-01-01)

Mutations in <it>PIK3CA </it>are infrequent in neuroblastoma
by: Mazanek Pavel, et al.
Published: (2006-07-01)

Mutations of <it>PIK3CA </it>in gastric adenocarcinoma
by: So Samuel, et al.
Published: (2005-03-01)

PATIENTS WITH METASTATIC CANCER OF UNKNOWN PRIMARY SITE: DIAGNOSTIC WORKUP AND THERAPEUTIC MANAGEMENT
by: Majeed H Alwan
Published: (2006-12-01)

The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib
by: Natalya V. Mazurina, et al.
Published: (2021-02-01)

Development of multiplex digital PCR assays for the detection of PIK3CA mutations in the plasma of metastatic breast cancer patients
by: Julien Corné, et al.
Published: (2021-08-01)

PIK3CA Mutational Analysis of Parathyroid Adenomas
by: Aaliyah Riccardi, et al.
Published: (2020-06-01)

PIK3CA mutant tumors depend on oxoglutarate dehydrogenase
by: Ilic, Nina, et al.
Published: (2017)

The Predictive Role of PIK3CA Mutation Status on PI3K Inhibitors in HR+ Breast Cancer Therapy: A Systematic Review and Meta-Analysis
by: Mingming Wang, et al.
Published: (2020-01-01)

Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients
by: Li Chen, et al.
Published: (2018-04-01)

Recurrent and Metastatic Characteristics and Prognosis of Advanced HER2-positive Breast Cancer Patients with Different HR Status
by: REN Yulin, et al.
Published: (2019-01-01)

BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
by: Soo Kyung Nam, et al.
Published: (2016-01-01)

Single nucleotide polymorphism rs17849071 G/T in the PIK3CA gene is inversely associated with follicular thyroid cancer and PIK3CA amplification.
by: Jeffrey C Xing, et al.
Published: (2012-01-01)

PIK3CA gene mutation associated with poor prognosis of lung adenocarcinoma
by: Zhang L, et al.
Published: (2013-05-01)

Surgical management for isolated macrodactyly in an adult PIK3CA mutant
by: C.J. Jacobs, et al.
Published: (2020-12-01)

Commentary: Pre-aesthetic workup: Should it be a part of pre-refractive surgery workup?
by: Ritika Sachdev
Published: (2021-01-01)

The role of the PIK3CA gene in the development and aging of the brain
by: Shaozhen Xie, et al.
Published: (2021-01-01)

PIK3CA alterations in Middle Eastern ovarian cancers
by: Uddin Shahab, et al.
Published: (2009-07-01)

Pik3ca is required for mouse uterine gland development and pregnancy.
by: Hye Jin Chang, et al.
Published: (2018-01-01)

PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.
by: Sherene Loi, et al.
Published: (2013-01-01)

Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma
by: Bardeesy Nabeel, et al.
Published: (2011-02-01)

P53 and PIK3CA Mutations in KRAS/HER2 Negative Ovarian Intestinal-Type Mucinous Carcinoma Associated with Mature Teratoma
by: Sarah Bouri, et al.
Published: (2020-01-01)

Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA
by: Joseph P. Garay, et al.
Published: (2021-08-01)

Radiologic workup of lung cancer
by: Al Ghanem Sara
Published: (2008-10-01)

Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2– advanced or metastatic breast cancer in Spain
by: Galve-Calvo E, et al.
Published: (2018-11-01)

PIK3CA-CDKN2A clonal evolution in metastatic breast cancer and multiple points cell-free DNA analysis
by: Maria Palmieri, et al.
Published: (2019-10-01)

High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated.
by: Camilla Krakstad, et al.
Published: (2012-01-01)

The virtual forum on the diagnosis and treatment of PIK3CA-mutated metastatic breast cancer. October 16th, 2020. Event review
by: Irina V. Poddubnaya, et al.
Published: (2021-02-01)

Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer.
by: Sherene Loi, et al.
Published: (2019-01-01)

Whole-Body SPECT/CT versus Planar Bone Scan with Targeted SPECT/CT for Metastatic Workup
by: Olivier Rager, et al.
Published: (2017-01-01)

Cannot write session to /tmp/vufind_sessions/sess_u18rihu169egnsvmgjftu89137